Несостоятельности трансплантата у реципиентов аллогенных гемопоэтических стволовых клеток: диагностика и лечение

Несостоятельность трансплантата – группа осложнений после трансплантации аллогенных гемопоэтических стволовых клеток, которая встречается по разным данным до 30 % случаев. В группу осложнений входят первичная и вторичная несостоятельность трансплантата, первичная, вторичная и транзиторная гипофункция трансплантата и отторжение трансплантата. Сложности диагностики заключаются в отсутствии единых критериев, принятых в трансплантационном сообществе, и в двоякой интерпретации этих осложнений по данным иностранной литературы. Целью данного обзора литературы было определить наиболее часто встречающиеся критерии различных видов несостоятельности трансплантата и тактику диагностики и лечения. В обзоре мы проанализировали данные различных источников литературы, дали определения несостоятельности и гипофункции трансплантата, проанализировали литературные данные по применяемым методам лечения данных состояний.

1. Xu ZL, Cheng YF, Zhang YY, et al. The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transplant. 2021;35(2):e14160. https://doi.org/10.1111/ctr.14160

2. Huang XJ. Overcoming graft failure after haploidentical transplantation: Is this a possibility?. Best Pract Res Clin Haematol. 2021;34(1):101255. https://doi.org/10.1016/j.beha.2021.101255

3. Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27(8):642-649. https://doi.org/10.1016/j.jtct.2021.04.007

4. Ren RR, Ma LM, Xie YX, Tian WW, Wang T. Effect of Donor Lymphocyte Infusion From Two Types of Donors on Mixed Chimerism With Secondary Graft Failure After Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022;28(3):152.e1-152.e7. https://doi.org/10.1016/j.jtct.2021.12.017

5. Yoshihara S, Maruya E, Taniguchi K, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant. 2012;47(4):508-515. https://doi.org/10.1038/bmt.2011.131

6. Alcazer V, Peffault de Latour R, Ader F, Labussière-Wallet H. Non-prise de greffe allogénique de cellules souches hématopoïétiques : définition et facteurs de risque identifiés [Graft failure after allogeneic hematopoietic stem cell transplantation: Definition and risk factors]. Bull Cancer. 2019;106(6):574-583. https://doi.org/10.1016/j.bulcan.2019.03.009

7. Kong Y. Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights ☆ . Semin Hematol. 2019;56(3):215-220. https://doi.org/10.1053/j.seminhematol.2018.08.004

8. Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127(5):646-657. https://doi.org/10.1182/blood-2015-10-672345

9. Хамаганова Е.Г., Кузьмина Л.А. Оценка HLA-совместимости и требования к HLA-типированию больного и донора при трансплантации аллогенных гемопоэтических стволовых клеток. Гематология и трансфузиология. 2019; 64(2):175-187. https://doi.org/10.35754/0234-5730-2019-64-2-175-187

10. Ciurea SO, Al Malki MM, Kongtim P, et al. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv. 2021;5(20):4031-4043. https://doi.org/10.1182/bloodadvances.2021004862

11. Ciurea SO, Al Malki MM, Kongtim P, et al. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv. 2021;5(20):4031-4043. https://doi.org/10.1182/bloodadvances.2021004862

12. Дубняк Д.С., Рисинская Н.В., Дроков М.Ю., Судариков А.Б. Мониторинг химеризма после трансплантации аллогенных гемопоэтических стволовых клеток. Трансплантология. 2022;14(4):488-499. https://doi.org/10.23873/2074-0506-2022-14-4-488-499.

13. Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice [published correction appears in Bone Marrow Transplant. 2014 Feb;49(2):319. Dosage error in article text]. Bone Marrow Transplant. 2014;49(2):168-173. https://doi.org/10.1038/bmt.2013.107

14. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320(4):197-204. https://doi.org/10.1056/NEJM198901263200401

15. Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT [published correction appears in Bone Marrow Transplant. 2013 Apr;48(4):616]. Bone Marrow Transplant. 2013;48(4):537-543. https://doi.org/10.1038/bmt.2012.239

16. Lund TC, Liegel J, Bejanyan N, et al. Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure. Am J Hematol. 2015;90(10):892-896. https://doi.org/10.1002/ajh.24111

17. Remberger M, Mattsson J, Olsson R, Ringdén O. Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure. Clin Transplant. 2011;25(1):E68-E76. https://doi.org/10.1111/j.1399-0012.2010.01324.x

18. Olsson RF, Logan BR, Chaudhury S, et al. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2015;29(8):1754-1762. https://doi.org/10.1038/leu.2015.75

19. Slot S, Smits K, van de Donk NW, et al. Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis. Bone Marrow Transplant. 2015;50(11):1424-1431. https://doi.org/10.1038/bmt.2015.172

20. Sun YQ, He GL, Chang YJ, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol. 2015;94(10):1699-1705. https://doi.org/10.1007/s00277-015-2440-x

21. Halahleh K, Gale RP, Da'na W, et al. Therapy of posttransplant poor graft function with eltrombopag. Bone Marrow Transplant. 2021;56(1):4-6. https://doi.org/10.1038/s41409-020-0975-5

22. Klyuchnikov E, El-Cheikh J, Sputtek A, et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 2014;20(3):382-386. https://doi.org/10.1016/j.bbmt.2013.11.034

23. Stasia A, Ghiso A, Galaverna F, et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(9):1440-1443. https://doi.org/10.1016/j.bbmt.2014.05.016

24. Chen J, Wang H, Zhou J, Feng S. Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation. Ther Adv Hematol. 2020;11:2040620720948743. Published 2020 Aug 17. https://doi.org/10.1177/2040620720948743

25. Bramanti S, Calafiore V, Longhi E et al. Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes. Biol Blood Marrow Transplant. 2019;25(7):1395-1406. https://doi.org/10.1016/j.bbmt.2019.02.020

26. Zhao Y, Gao F, Shi J, et al. Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019;25(9):1898-1907. https://doi.org/10.1016/j.bbmt.2019.05.036

27. Рудакова Т.А., Кулагин А.Д., Климова О.У. и др. Тяжелая гипофункция трансплантата после аллогенной трансплантации гемопоэтических стволовых клеток у взрослых пациентов: частота, факторы риска, исходы. 2019;12(3):309–18. https://doi.org/10.21320/2500-2139-2019-12-3-309-318

28. Mohty R, Brissot E, Battipaglia G, et al. CD34+-selected stem cell "Boost" for poor graft function after allogeneic hematopoietic stem cell transplantation. Curr Res Transl Med. 2019;67(3):112-114. https://doi.org/10.1016/j.retram.2018.12.003

29. McLornan DP, Hernandez-Boluda JC, Czerw T, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party [published correction appears in Leukemia. 2021 Sep 1;:]. Leukemia. 2021;35(9):2445-2459. https://doi.org/10.1038/s41375-021-01294-2

30. Bittencourt H, Rocha V, Filion A, et al. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transplant. 2005;36(5):431-435. https://doi.org/10.1038/sj.bmt.1705072

31. Tamari R, Ramnath S, Kuk D, Sauter CS, Ponce DM, Devlin S, et al. Poor Graft Function in Recipients of T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplants (HSCT) Is Mostly Related to Viral Infections and Anti-Viral Therapy. Blood. 2012 Nov 16;120(21):3147.

32. Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT [published correction appears in Bone Marrow Transplant. 2013 Apr;48(4):616]. Bone Marrow Transplant. 2013;48(4):537-543. https://doi.org/10.1038/bmt.2012.239

33. Woodard P, Tong X, Richardson S, et al. Etiology and outcome of graft failure in pediatric hematopoietic stem cell transplant recipients. J Pediatr Hematol Oncol. 2003;25(12):955-959. https://doi.org/10.1097/00043426-200312000-00010

34. Fleischhauer K, Locatelli F, Zecca M, et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood. 2006;107(7):2984-2992. https://doi.org/10.1182/blood-2005-08-3374

35. Rondón G, Saliba RM, Khouri I, et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant. 2008;14(8):859-866. https://doi.org/10.1016/j.bbmt.2008.05.005

36. Sun YQ, Wang Y, Wang FR, et al. Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor. Front Med (Lausanne). 2021;8:604085. Published 2021 Jun 4. https://doi.org/10.3389/fmed.2021.604085

37. Albert MH, Sirin M, Hoenig M, et al. Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders. Bone Marrow Transplant. 2021;56(9):2248-2258. https://doi.org/10.1038/s41409-021-01323-9

38. Philogene MC, Sikorski P, Montgomery RA, Leffell MS, Zachary AA. Differential effect of bortezomib on HLA class I and class II antibody. Transplantation. 2014;98(6):660-665. https://doi.org/10.1097/TP.0000000000000132

39. Lund TC, Liegel J, Bejanyan N, et al. Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure. Am J Hematol. 2015;90(10):892-896. https://doi.org/10.1002/ajh.24111

40. Schriber J, Agovi MA, Ho V, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant. 2010;16(8):1099-1106. https://doi.org/10.1016/j.bbmt.2010.02.013

41. Ciurea SO, Cao K, Fernandez-Vina M, et al. Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2019;54(5):784. https://doi.org/10.1038/s41409-018-0332-0

42. Rattani N, Matheny C, Eckrich MJ, Madden LM, Quigg TC. Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation. Cancer Rep (Hoboken). 2022;5(1):e1403. https://doi.org/10.1002/cnr2.1403

43. Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, Dini G. Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol. 2004;65(5):416-422. https://doi.org/10.1016/j.humimm.2004.02.013

44. Guardiola P, Kuentz M, Garban F, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol. 2000;111(1):292-302. https://doi.org/10.1046/j.1365-2141.2000.02306.x

45. Chewning JH, Castro-Malaspina H, Jakubowski A, et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant. 2007;13(11):1313-1323. https://doi.org/10.1016/j.bbmt.2007.07.006

46. Jabbour E, Rondon G, Anderlini P, et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2007;40(5):431-435. https://doi.org/10.1038/sj.bmt.1705760

47. Remberger M, Watz E, Ringdén O, Mattsson J, Shanwell A, Wikman A. Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(6):675-682. https://doi.org/10.1016/j.bbmt.2007.01.084

48. Mahat U, Rotz SJ, Hanna R. Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020;26(3):e65-e73. https://doi.org/10.1016/j.bbmt.2019.12.003

49. Uria-Oficialdegui ML, Alonso L, Benitez-Carabante MI, Renedo B, Oliveras M, Diaz-de-Heredia C. Use of eltrombopag for the treatment of poor graft function after hematopoietic stem cell transplantation in children. Pediatr Transplant. 2021;25(4):e14010. https://doi.org/10.1111/petr.14010

50. Giammarco S, Sica S, Chiusolo P, et al. Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. Int J Hematol. 2021;114(2):228-234. https://doi.org/10.1007/s12185-021-03153-3

51. Larocca A, Piaggio G, Podestà M, et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica. 2006;91(7):935-940.

52. Chandra S, Bleesing JJ, Jordan MB, et al. Post-Transplant CD34 + Selected Stem Cell "Boost" for Mixed Chimerism after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Children and Young Adults with Primary Immune Deficiencies. Biol Blood Marrow Transplant. 2018;24(7):1527-1529. https://doi.org/10.1016/j.bbmt.2018.03.013

53. Ghobadi A, Fiala MA, Ramsingh G, et al. Fresh or Cryopreserved CD34 + -Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2017;23(7):1072-1077. https://doi.org/10.1016/j.bbmt.2017.03.019

54. Askaa B, Fischer-Nielsen A, Vindeløv L, Haastrup EK, Sengeløv H. Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning. Bone Marrow Transplant. 2014;49(5):720-721. https://doi.org/10.1038/bmt.2014.5

55. Mahat U, Rotz SJ, Hanna R. Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020;26(3):e65-e73. https://doi.org/10.1016/j.bbmt.2019.12.003

56. Cuadrado MM, Szydlo RM, Watts M, et al. Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. Haematologica. 2020;105(11):2639-2646. Published 2020 Nov 1. https://doi.org/10.3324/haematol.2019.226340

57. Haen SP, Schumm M, Faul C, Kanz L, Bethge WA, Vogel W. Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation. J Cancer Res Clin Oncol. 2015;141(12):2241-2251. https://doi.org/10.1007/s00432-015-2027-x